The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab

Journal of Pharmaceutical Sciences

Volumn 95, Issue 6, 2006, Pages 1258-1268

  Wu, Benjamin ^a   Joshi, Amita ^a   Ren, Song ^a   Ng, Chee ^a  

^a GENENTECH INC   (United States)

Author keywords

Anti CD11a; Antibody; Efalizumab; Mechanism based modeling; muM17; Pharmacodynamic; Pharmacokinetic; Psoriasis; Raptiva

Indexed keywords

EFALIZUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MUM17; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOUSE; MULTICENTER STUDY; MULTIPLE DRUG DOSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PSORIASIS VULGARIS; SCANTY HAIR; T LYMPHOCYTE;

EID: 33745053380     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20475     Document Type: Article

References (16)

1. Bos JD, De Rie MA. 1999. The pathogenesis of psoriasis: Immunological facts and speculations. Immunol Today 20:40-46.
2. Krueger JG. 2002. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 46:1-23; quiz 23-26.
3. Norris DA, Travers JB, Leung DY. 1997. Lymphocyte activation in the pathogenesis of psoriasis. J Invest Dermatol 109:1-4.
4. Larson RS, Springer TA. 1990. Structure and function of leukocyte integrins. Immunol Rev 114: 181-217.
5. Griffiths TW, Griffiths CE, Voorhees JJ. 1995. Immunopathogenesis and immunotherapy of psoriasis. Dermatol Clin 13:739-749.
6. Shang XZ, Issekutz AC. 1998. Contribution of CD11a/CD18, CD11b/CD18, ICAM-1 (CD54) and - 2 (CD102) to human monocyte migration through endothelium and connective tissue fibroblast barriers. Eur J Immunol 28:1970-1979.
7. Werther WA, Gonzalez TN, O'Connor SJ, McCabe S, Chan B, Hotaling T, Champe M, Fox JA, Jardieu PM, Berman PW, Presta LG. 1996. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 157:4986-4995.
8. Bauer RJ, Dedrick RL, White ML, Murray MJ, Garovoy MR. 1999. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 27:397-420.
9. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M. 2002. Psoriasis as a model for T-cell-mediated disease: Immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 138:591-600.
10. Champe M, McIntyre BW, Herman PW. 1995. Monoclonal antibodies that block the activity of leukocyte function-associated antigen 1 recognize three discrete epitopes in the inserted domain of CD11a. J Biol Chem 270:1388-1394.
11. Reimann KA, Waite BC, Lee-Parritz DE, Lin W, Uchanska-Ziegler B, O'Connell MJ, Letvin NL. 1994. Use of human leukocyte-specific monoclonal antibodies for clinically immunqphenotyping lymphocytes of rhesus monkeys. Cytometry 17:102-108.
12. Nakakura EK, McCabe SM, Zheng B, Shorthouse RA, Scheiner TM, Blank G, Jardieu PM, Morris RE. 1993. Potent and effective prolongation by anti-LFA-1 monoclonal antibody monotherapy of non-primarily vascularized heart allograft survival in mice without T cell depletion. Transplantation 55:412-417.
13. Clarke J, Leach W, Pippig S, Joshi A, Wu BM, House R, Beyer J. 2004. Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody. Regul Toxicol Pharmacol 40:219-226.
14. Mortensen DL, Walicke PA, Wang X, Kwon P, Kuebler P, Gottlieb AB, Krueger JG, Leonardi C, Miller B, Joshi A. 2005. The pharmacokinetics and pharmacodynamics of efalizumab following 12 weeks of subcutaneous treatment in subjects with moderate to severe plaque psoriasis in a Phase I, open label, multi center study. J Clini Pharmacol 45:286-298.
15. Hing JP, Woolfrey SG, Greenslade D, Wright PM. 2001. Is mixed effects modeling or naive pooled data analysis preferred for the interpretation of single sample per subject toxicokinetic data? J Pharmacokinet Pharmacodyn 28:193-210.
16. Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, Ward ES. 1996. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 26:690-696.